OOIR: Observatory of International Research

Papers

(The TQCC of Hematology-American Society of Hematology Education Program is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Managing toxicities of Bruton tyrosine kinase inhibitors	77
Therapeutic development and current uses of BCL-2 inhibition	68
Platelet transfusion refractoriness: how do I diagnose and manage?	40
Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors	39
Preventing infections in children and adults with asplenia	38
Bispecifics, trispecifics, and other novel immune treatments in myeloma	38
Monoclonal gammopathies of clinical significance	37
Updates in infection risk and management in acute leukemia	34
Gene therapy for hemophilia	33
Management of AL amyloidosis in 2020	32
Therapy for lower-risk MDS	32
Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes	30
Next-generation cell therapies: the emerging role of CAR-NK cells	27
Inferior vena cava filters: a framework for evidence-based use	26
Evidence-Based Minireview: Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review	23
Does ABO and RhD matching matter for platelet transfusion?	23
Management of Waldenström macroglobulinemia in 2020	23
Updates in chronic graft-versus-host disease	23
Have we reached a molecular era in myelodysplastic syndromes?	22
Outpatient transfusions for myelodysplastic syndromes	22
Advances in the management of α-thalassemia major: reasons to be optimistic	22
Future of CAR T cells in multiple myeloma	21
“TEG talk”: expanding clinical roles for thromboelastography and rotational thromboelastometry	21
Combining antiplatelet and anticoagulant therapy in cardiovascular disease	20
Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia	20

What to use to treat AML: the role of emerging therapies	19
Prevention and treatment of postpartum hemorrhage: focus on hematological aspects of management	19
Increasing access to allotransplants in the United States: the impact of race, geography, and socioeconomics	19
Allogeneic hematopoietic cell transplantation for older patients	19
Modern management of Fanconi anemia	19
Gene therapy for sickle cell disease: where we are now?	19
Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic di	19
Dyskeratosis congenita and telomere biology disorders	19
Diagnosis and management of iron deficiency in chronic inflammatory conditions (CIC): is too little iron making your patient sick?	18
First-generation vs second-generation tyrosine kinase inhibitors: which is best at diagnosis of chronic phase chronic myeloid leukemia?	17
High-risk multiple myeloma: how to treat at diagnosis and relapse?	16
Optimizing the management of chronic pain in sickle cell disease	16
Treatment of immune-mediated cytopenias in patients with primary immunodeficiencies and immune regulatory disorders (PIRDs)	16
Antibodies and bispecifics for multiple myeloma: effective effector therapy	16
Special pre- and posttransplant considerations in inherited bone marrow failure and hematopoietic malignancy predisposition syndromes	16
Identifying potential germline variants from sequencing hematopoietic malignancies	16
Increasing access to allogeneic hematopoietic cell transplant: an international perspective	16
Does aspirin prevent venous thromboembolism?	15
Women and bleeding disorders: diagnostic challenges	15
Management of heavy menstrual bleeding on anticoagulation	15
How to avoid the problem of erythrocyte alloimmunization in sickle cell disease	15
Approach to the patient with suspected hypereosinophilic syndrome	15
Epidemiology and treatment of priapism in sickle cell disease	14
Blast and accelerated phase CML: room for improvement	14
Practice patterns and outcomes for adults with acute myeloid leukemia receiving care in community vs academic settings	14
Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms	14
Challenges in chronic transfusion for patients with thalassemia	14
Evidence-Based Minireview: Abnormal uterine bleeding in users of rivaroxaban and apixaban	14
Hereditary hemorrhagic telangiectasia (HHT): a practical guide to management	14
Double-hit lymphoma: optimizing therapy	14
Chemotherapy-free frontline therapy for CLL: is it worth it?	14
β-Thalassemia: evolving treatment options beyond transfusion and iron chelation	13
Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop	13
Indications for transfusion in the management of sickle cell disease	13
Relapsed ALL: CAR T vs transplant vs novel therapies	13
How to recognize and manage COVID-19-associated coagulopathy	13
How do we sequence therapy for marginal zone lymphomas?	13
How to manage CML patients with comorbidities	12
Mechanisms of somatic transformation in inherited bone marrow failure syndromes	12
Hemophilia gene therapy: ushering in a new treatment paradigm?	12
Rituximab and eculizumab when treating nonmalignant hematologic disorders: infection risk, immunization recommendations, and antimicrobial prophylaxis needs	12
Transformed lymphoma: what should I do now?	12
Cellular therapy for multiple myeloma: what's now and what's next	12
Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP	12
Inherited microcytic anemias	11
COVID-19 and thrombosis: searching for evidence	11
Heparin-induced thrombocytopenia and cardiovascular surgery	11
Genomics of MPN progression	11
How to evaluate and treat the spectrum of TMA syndromes in pregnancy	11
Global look at nutritional and functional iron deficiency in infancy	11

Molecular prognostication in Ph-negative MPNs in 2022	11
Extrahematopoietic manifestations of the short telomere syndromes	11
Diamond-Blackfan anemia	11
Allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency	11
Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies	10
Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events	10
Strategies for introducing palliative care in the management of relapsed or refractory aggressive lymphomas	10
Social aspects of chronic transfusions: addressing social determinants of health, health literacy, and quality of life	10
Sequencing multiple myeloma therapies with and after antibody therapies	10
Direct oral anticoagulant (DOAC) interference in hemostasis assays	10
Achieving MRD negativity in AML: how important is this and how do we get there?	10
Lower risk but high risk	10
When are idiopathic and clonal cytopenias of unknown significance (ICUS or CCUS)?	10
Treatment of Richter's syndrome	10
When does a PNH clone have clinical significance?	9
In 2022, which is preferred: haploidentical or cord transplant?	9
Novel targets in aggressive lymphoma	9
Evidence-Based Minireview: Treatment of relapsed chronic lymphocytic leukemia after venetoclax	9
How to evaluate for immunodeficiency in patients with autoimmune cytopenias: laboratory evaluation for the diagnosis of inborn errors of immunity associated with immune dysregulation	9
Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates?	9
Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy	9
How immunodeficiency can lead to malignancy	9
Hematology 2022—what is complete HLA match in 2022?	9
Transplant for TP53-mutated MDS and AML: because we can or because we should?	9
CAR T cells vs allogeneic HSCT for poor-risk ALL	9